HLA-DQA1*05:01 and DQA1*05:05 inform choice of anti-tumor necrosis factor and concomitant use of immunomodulators in patients with inflammatory bowel disease. [PDF]
J Crohns ColitisZhang Q +5 more
europepmc +1 more source
A Case of Refractory Cutaneous Sarcoidosis Successfully Treated with Infliximab
Roudha Al-Dehneem
openalex +2 more sources
Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence. [PDF]
Kidney Int RepYoussef N +11 more
europepmc +1 more source
Transient Visual Loss due to Infliximab Administration: A New Adverse Event to Biologic Therapy in Crohn's Disease. [PDF]
ACG Case Rep JCoelho H, Dias MT, Oliveira AM.
europepmc +1 more source
Effectiveness of Infliximab for Refractory Nonischemic Cerebral Enhancing Foreign-Body Granulomatous Lesions After Endovascular Therapy. [PDF]
NeurologyAboseif A +8 more
europepmc +1 more source
Disseminated tuberculosis and heart failure in a patient receiving infliximab for psoriasis
, 2014 Ercan Çalışkan +6 more
openalex +1 more source
Pharmacokinetic Model Selection for Personalized Infliximab Dosing in IBD. [PDF]
CPT Pharmacometrics Syst PharmacolChaiben S +4 more
europepmc +1 more source
<i>HLA-C</i>*03:04:01 and <i>HLA-B</i>*15:18:01 but not <i>HLA-DQA1</i>*05 associated with anti- tumor necrosis factor antibody formation in Taiwanese inflammatory bowel disease patients. [PDF]
World J GastroenterolWeng MT +8 more
europepmc +1 more source
P0936 Switch from intravenous to subcutaneous infliximab: first subcutaneous dose and cumulative area under curve [PDF]
Núria Padullés Zamora +7 more
openalex +1 more source